SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

SL Science leadership co-authored a peer-reviewed framework in Biomedicines outlining clinical development strategies for γδ T cell therapy in glioblastoma. The publication establishes a roadmap for future trials and validates the company's strategic focus on allogeneic, off-the-shelf cell therapies, though it remains independent of specific product candidates.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.